The effectiveness of ARISCAT Risk Index, other scoring systems, and parameters in predicting pulmonary complications after thoracic surgery

Gülay Ülger, MD*, Hilal Sazak, MD, Ramazan Baldemir, MD, Musa Zengin, MD, Oya Kaybal, MD, Funda İncekara, MD, Ali Alagöz, MD

Abstract

The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) risk index, which is frequently used in nonthoracic surgery, may not be sufficient to predict postoperative pulmonary complications (PPCs). We aimed to evaluate the effectiveness of the ARISCAT risk index, ASA, preoperative albumin level, neutrophil/lymphocyte ratio (NLR), and other parameters in predicting PPCs after thoracic surgery.

Patients undergoing elective thoracic surgery with 1-lung ventilation (OLV) were prospectively analyzed. Demographic data, ARISCAT score, ASA, Nutritional Risk Score-2002, NLR, white blood cell counts, albumin, hemoglobin levels, intraoperative complications, postoperative average visual analogue scale (VAS) score for pain at the 24th-hour, the length of stay in the postoperative intensive care unit, chest tube removal time, postoperative complications, and discharge time were recorded. Patients were assessed for morbidity and mortality on the 90th-day.

120 patients' data were analyzed. PPCs developed in 26 patients. The development of PPCs was statistically significant in patients with high ARISCAT scores \( P = .002 \), high ARISCAT grades \( P = .009 \), and ASA III \( P = .002 \). The albumin level was statistically significantly lower in patients who had mortality within 3 months \( P = .007 \). When scoring systems and laboratory parameters were evaluated together, patients with high ARISCAT grade, Albumin < 35g/L, and ASA III had significantly higher development of PPCs \( P = .004 \).

ARISCAT risk index and ASA were found to be significant in predicting PPCs after thoracic surgery. They were also valuable when evaluated in combination with preoperative albumin levels. Additionally, age, male gender, duration of surgery, and duration of OLV were also found to be associated with PPCs.

Abbreviations: ARISCAT = The Assess Respiratory Risk in Surgical Patients in Catalonia, ASA = American Society of Anesthesiologists, BMI = Body mass index, COPD = Chronic obstructive pulmonary disease, NLR = Neutrophil/lymphocyte ratio, NRS-2002 = Nutritional risk score, OLV = One-lung ventilation, PCA = Patient-controlled analgesia, PONV = Postoperative nausea and vomiting, PPCs = Postoperative pulmonary complications, SD = Standard deviations, VAS = Visual analog scale, VATS = Video-assisted thoracoscopic surgery.

Keywords: American Society of Anesthesiologist (ASA), albumin, postoperative pulmonary complications, The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT), thoracic surgery

Financial Disclosures: None.

Informed Consent Statement: All patients were informed about the study, and their written informed consent was obtained.

The datasets generated during and/or analyzed in the current study are not publicly available, but are available from the corresponding author on reasonable request.

IRB: Keçiören Training and Research Hospital Ethical Committee; ID: 2012-KAEK-15/2230 Date: 03.09.2021.

Compliance with Ethical Standards: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration (as revised in 2013) and its later amendments or comparable ethical standards.

Ethical Statement: The study was performed in agreement with the approval of the Ethics Committee (Date: 03.09.2021, number: 2012-KAEK-15/2230).

Clinical trial number and registry URL: This “The Effectiveness of ARISCAT Risk Index, Other Scoring Systems, and Parameters in Predicting Pulmonary Complications after Thoracic Surgery” trial was registered on www.clinicaltrials.gov under the identifier NCT04995939. This manuscript adheres to the applicable Consolidated Standards of Reporting Trials (CONSORT) guidelines.
1. Introduction

Postoperative pulmonary complications (PPCs) include complications affecting the respiratory system after anesthesia and surgery. These complications are common, difficult to predict, and have significant effects on patients.11 PPCs emerge as a major risk. It affects the morbidity and mortality of patients and is effective in the length of hospital stay and hospital costs.22 The incidence of PPCs in the general population undergoing surgery varies between 2% and 5.6%.3 This rate was 19–59% after thoracic surgery, 16–17% after upper-abdomen surgery, and 0–5% after lower-abdomen surgery.6–11 Because of the high incidence and risks, it is important to predict PPCs before surgery and take the necessary precautions according to the surgical methods.

The American Society of Anesthesiologists (ASA) physical status assessment is used to subjectively predict the health status of patients before surgery. Although it was originally a scoring system created for statistical data collection and reporting for anesthesia, it is now used to predict perioperative risk.6,7 However, ASA physical status assessment may not be sufficient to predict complications that may develop in certain surgical groups.8 Therefore, many different scoring systems are used during the preoperative period to determine the risk status of patients. There are also studies on scoring systems that can be effective in predicting PPCs. The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) risk index is a frequently used scoring system. The ARISCAT risk index is derived using many variables such as age, oxygen saturation, previous respiratory infection, anemia, abdominal or thoracic surgery, duration of operation, and emergency surgery.9 The ARISCAT risk index was developed to predict the risk of PPCs and has shown promising results.10

The ARISCAT risk index is mostly used in operations other than thoracic surgery. Since the thoracic wall, mediastinum, or lungs are directly intervened in thoracic surgery cases, the expected PPCs in these patients may be different than those expected in other surgical groups. Therefore, the ARISCAT risk index may be insufficient to evaluate PPCs in thoracic surgery. Many parameters obtained from the blood count, such as the neutrophil/lymphocyte ratio (NLR), have prognostic value in cardiovascular and oncological diseases and can be a potential marker of systemic inflammation.11–14 Many studies reported that high NLR, low hemoglobin, and low serum albumin levels show an unfavorable prognosis in lung cancer.15–17 Additionally, many studies have shown that blood values such as white blood cell count, neutrophil count, and NLR, are valuable in predicting diagnosis, mortality, complications, and hospital stay in cardiovascular diseases.14–20

We hypothesize that various scoring systems and laboratory parameters may be more effective in predicting PPCs in patients undergoing thoracic surgery. In this study, we evaluated the effectiveness of the ARISCAT risk index, ASA physical status, nutritional risk score (NRS-2002), NLR, albumin, hemoglobin level, and the combined use of parameters in predicting PPCs after thoracic surgery.

2. Materials and Methods

2.1. Study design

After Ethics Committee approval was obtained for this prospective observational study (Date: 03.09.2021, number: 2012-KAEK-13/2230), it was performed in a tertiary thoracic surgery center between March 2021 and August 2021. The following patients were included in the study: those undergoing elective thoracotomy or video-assisted thoracoscopic surgery (VATS) under general anesthesia with 1-lung ventilation (OLV); those between the ages of 18–75, in the ASA physical status I-II-III risk group, with a body mass index (BMI) 18.5–35 kg/m², and with an expected operation time of more than 60 minutes. The study was registered to the Clinical Trial (clinicaltrials.gov Identifier: NCT04995939).

Patients who underwent bilateral thoracic surgery, those with chronic obstructive pulmonary disease (COPD) in class III and IV according to the GOLD classification, with advanced heart failure, coronary heart disease, sleep apnea syndrome, previous COVID-19 pneumonia, and previous lung surgery, with neuromuscular disease, and intracranial tumor, and those who had any of the PPCs before anesthesia induction were excluded from the study. The European joint task force published a guideline for the perioperative clinical outcome in 2015 and specified the definition of PPCs.23 Later, Miskovic and Lumb revised this definition and stated that PPCs include complications such as aspiration, infiltration, pulmonary infection, atelectasis (required bronchoscopic intervention), cardiopulmonary edema, pleural effusion, pneumothorax, pulmonary embolism, empyema, and hemoptysis.11 In the study PPCs also included prolonged air leakage which was a persistent air leak for more than 5 to 7 days after surgery.

Written informed consent was obtained from the patients 1 day before the operation. During the preoperative anesthetic evaluation, the following data were recorded: Gender, age, height, body weight, BMI, ARISCAT score, ARISCAT risk classification, ASA physical status, and NRS-2002. ARISCAT risk score classification is shown in Table 1.14 The NLR, white blood cell count, albumin, hemoglobin, preoperative oxygen saturation, pulmonary function test results, history of previous surgery, and concomitant diseases were also noted. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count.

During the intraoperative process; anesthesia duration, total OLV time, blood loss, urine output, regional anesthesia management, duration of operation, surgical procedure (VATS or thoracotomy), surgery performed, complications requiring intraoperative treatment, type of neuromuscular block antagonist applied at the end of surgery were recorded. The type and total amount of blood product and fluid administered were also noted.

The volumes of crystalloids, colloids, blood products, and the doses of vasoactive drugs administered within 24 hours after leaving the operating room were recorded. Additionally,

### Table 1

**Parameters of the ARISCAT score and risk classification.**14

| Score components | Risk score |
|------------------|------------|
| Age              | ≤50 year   | 0          |
|                  | 51–80 year | 3          |
|                  | >80 year   | 16         |
| Preoperative oxygen saturation | ≥96% | 0 |
|                  | 91–95%     | 8          |
|                  | < 90%      | 24         |
| Respiratory infection in past 1 month | No | 0 |
|                  | Yes        | 17         |
| Preoperative hemoglobin < 10 g/dl | No | 0 |
|                  | Yes        | 11         |
| Incision          | Peripheral incision | 0 |
|                  | Upper abdominal incision | 15 |
|                  | Intrathoracic incision | 24 |
| Surgery duration  | <2 hours   | 0          |
|                  | 2–3 hours  | 16         |
|                  | >3 hours   | 23         |
| Emergency procedure | No | 0 |
|                  | Yes        | 8          |

| Risk             | ARISCAT Score |
|------------------|---------------|
| Low              | < 26 (1.6%)   |
| Medium/Intermediate | 26–44 (13.3%) |
| High             | > 45 (42.1%)  |
2.2. General anesthesia

Patients were monitored in the operating room under the ASA standards and 0.03 mg/kg midazolam was administered intravenously to the patients for premedication. Following preoxygenation; anesthesia was induced with 2–2.5 mg/kg propofol, 1–1.5 mcg/kg fentanyl, and 0.1 mg/kg vecuronium intravenously. After the intubation with a left-sided double-lumen endobronchial tube, anesthesia was maintained by administering 2–3% sevoflurane in oxygen and air mixture. Intraoperative lung-protective ventilation (tidal volume 5–7 mL/kg, positive end-expiratory pressure 5–7 cmH₂O, and ventilatory plateau pressures below 30 cmH₂O whenever possible) was administered in all patients.[22] Furthermore, the shortest possible OLV duration was tried to be applied.

2.3. The block procedure

The block procedure was performed under general anesthesia before the skin incision to prevent the patient anxiety and ensure comfort. Thus, preemptive analgesia was also achieved. Following the anesthesia induction, the thoracic paravertebral block or erector spinae plane block was performed under ultrasound guidance when the patients were in the lateral decubitus position. For both blocks, 20 ml of 0.25% bupivacaine was injected.

2.4. Analgesia protocol

Before the end of the surgical procedure; metoclopramide, to prevent PONV; dexketoprofen (50 mg), and tramadol (100 mg) were given to the patients intravenously. Intravenous morphine was administered via patient-controlled analgesia (PCA) pump for 24 hours in the postoperative surgical intensive care unit. The PCA pump’s dose delivery was limited to administering a bolus dose of 1 mg morphine and delivering a maximum dose of 12 mg morphine in total within 4 hours with lockout intervals of 15 minutes. Paracetamol 1g every 8 hours and dexketoprofen 50mg twice daily were administered intravenously for multimodal analgesia. As a rescue analgesic agent, 0.5 mg/kg tramadol was given to patients intravenously when a score of VAS at coughing ≥ 4. Side effects such as allergic reactions, hypotension, PONV, and itching were recorded.

2.5. Statistical analysis

Data analyses were performed with SPSS for Windows, version 22.0 (SPSS Inc., Chicago, IL, United States). Whether the distribution of continuous variables was normal or not was determined by the Kolmogorov Smirnov test. Levene test was used for the evaluation of homogeneity of variances. Unless specified otherwise, continuous data were described as mean ± standard deviation (SD) for normal distributions, and median (interquartile range) for skewed distributions. Categorical data were described as the number of cases (%). Statistical analysis differences in normally distributed variables between 2 independent groups were compared by Student t-test. Mann-Whitney U tests were applied for comparisons of not normally distributed data. Categorical variables were compared using Pearson chi-square test or Fisher exact test. We evaluated the degrees of the relationship between variables with Spearman correlation analysis. The differences in not normally distributed variables among more than 2 independent groups were analyzed by the Kruskal-Wallis test. When the P-value from Kruskal-Wallis test statistics was statistically significant, the post hoc Conover-Inman test of multiple comparisons was used to know which group differed from which others. No specific adjustment was made for the P-value in multiple comparisons. When the Mann-Whitney-U tests are used, the Bonferroni correction is generally applied to reduce the risk of Type-I error in multiple comparisons. However, we did not use the Mann-Whitney-U test with Bonferroni correction. Instead, we applied the Conover-Inman test, which can be used as a post hoc test for the Kruskal Wallis test and which is included in the SPSS 22 package program. P-value < 0.05 was accepted as a significant level on all statistical analyses.

2.6. Sample size

The sample size was calculated using G*Power® software version 3.1.9.2 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, Germany). The sample size was calculated for the chi-square test, which was used for testing the main hypothesis of the present study. Depending on the results of previous research with 2-sided (two tails) Type-I error 0.05 and power of 80% (1- β = 0.8), effect size (d) factor 0.349, should involve at least 106 patients.[23]

2.7. Power analysis

The post hoc power was calculated using G*Power® software version 3.1.9.2 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, Germany). The power was calculated for the chi-square test, which was used for testing the main hypothesis of the present study (ARISCAT score in those with and without PPCs). Depending on the results of the previous research with 2-sided (two tails) Type-I error 0.05 and effect size (d) factor 0.619, post hoc power calculated as %77.2.[23]

3. Results

A total of 432 patients underwent thoracic surgery in the tertiary center between March 2021 and August 2021. 133 patients were eligible for the study. Among these patients, 120 patients were analyzed (Fig. 1). Demographic data and surgical characteristics of the patients are given in Table 2.

PPCs developed in 26 patients. Atelectasis was observed in 14 patients (46.6%), prolonged air leakage in 12 patients (40%), pulmonary embolism in 3 patients (10%), and pneumonia in 1 patient (3.3%). More than 1 complication was seen in 4 patients.

The development of PPCs has no statistically significant relationship with diagnosis, BMI, operation direction, and operation type. The age of the patients who developed PPCs was statistically significantly higher (P = .008). As patients’ age increased, chest tube removal time (P = .008) and discharge time (P = .005) increased statistically significantly and there was a low positive correlation. The number of men who developed PPCs was statistically significantly higher (P = .005). The discharge time of male patients was statistically significantly higher (P = .039). The left-sided operation rate was statistically significantly higher in patients who had mortality within 3 months (P = .045). When the patients who developed PPCs,
were evaluated in terms of surgery, in those who had a lobectomy, wedge resection, and segmentectomy the PPCs were statistically significantly higher ($P = .013$), and chest tube removal time ($P < .001$) and discharge time ($P < .001$) statistically significantly increased as OLV duration increased (Table 3 and Table 4).

There was no statistically significant correlation between the development of PPCs and preoperative NRS-2002, albumin, NLR, and hemoglobin. The ARISCAT score ($P = .002$) and the ARISCAT grade ($P = .009$) were found to be statistically significantly higher in patients who developed PPCs. Chest tube removal time ($P = .004$) and discharge time ($P < .001$) increased statistically significantly as ARISCAT score and grade increased. A low degree of positive correlation was found between the ARISCAT score and chest tube removal time ($P < .001$) and discharge time ($P < .001$). The development of PPCs was found to be statistically significantly higher in patients with ASA physical status class of 3 ($P = .002$). It was observed that the albumin level was statistically significantly lower in those with 3-month mortality ($P = .007$). When the patients were evaluated in terms of NRS-2002, it was observed that all patients had NRS-2002 scores below 3 (Table 5).

When scoring systems and laboratory parameters were evaluated in different combinations, the incidence of PPCs in combination-I was found to be statistically significantly higher ($P = .004$). Chest tube removal time ($P = .002$) and discharge time ($P = .003$) were also observed to be statistically significantly longer in combination-I (Table 6).

When the 3-month mortality, discharge time, and chest tube removal time of the patients who developed PPCs were evaluated, in the patients with PPCs discharge time and chest tube removal time were found to be statistically significantly higher ($P < .001$).

### 4. Discussion

According to the literature review, this is the first prospective observational study in which different scoring systems and laboratory parameters were evaluated together with the ARISCAT scoring system for predicting PPCs after thoracic surgery to our knowledge. The incidence of PPCs was 21.7% and the 3-month mortality rate was 3.3% in the present study. Study results showed that the incidence of PPCs is higher with advancing age and in men. Advancing age also prolonged the

---

**Table 2. Demographic and surgical characteristics of the patients.**

| All patients (n:120) |  |
|----------------------|----------------------|
| Age (yr) | 55.48 ± 12.76  
| (50.50–65.00)  |
| BMI (kg/m²) | 27.89 ± 5.03  
| (23.38–31.24)  |
| Gender |  |
| Women | 42 (35.0%)  |
| Men | 78 (65.0%)  |
| Diagnosis |  |
| Mass, malignant | 99 (82.5%)  |
| Bronchiectasis | 5 (4.1%)  |
| Hydatid cyst | 9 (7.5%)  |
| Pleural thickening | 2 (1.7%)  |
| Interstitial lung disease | 2 (1.7%)  |
| Other | 3 (2.5%)  |
| Co-morbidity |  |
| Hypertension | 39 (32.5%)  |
| Diabetes mellitus | 28 (23.3%)  |
| Coronary artery disease | 18 (15.0%)  |
| Chronic obstructive lung disease–asthma | 13 (10.8%)  |
| Gout | 5 (4.2%)  |
| Rhythm disorders | 1 (0.8%)  |
| Extrapulmonary malignancy | 5 (4.2%)  |
| Cerebrovascular event | 3 (2.5%)  |
| Other | 6 (5.0%)  |

Continuous variables are expressed as either the mean ± standard deviation or median (minimum-maximum) and categorical variables are expressed as either frequency or percentage. BMI = body mass index.
Table 3
PPCs, chest tube removal time, discharge time, and three-month mortality characteristics by patients’ demographic data and diagnosis.

|                                      | PPCs positive n:94 (78.3%) | PPCs negative n:26 (21.7%) | Chest tube removal time (Day) | Discharge time (Day) | 3-Month mortality positive n:4 (3.3%) | 3-Month mortality negative n:116 (96.7%) |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------|---------------------------------------|----------------------------------------|
| Gender                               | 56.5 (16)                   | 62 (13)                     | r:0.243                     | r:0.256              | 55.5 (6)                              | 58 (15.5)                             |
| **P value**                          | .008†                       | .008                        | .005||                      | .95†                 |                                       |                                        |
| BMI                                  | 26.99 (7.47)                | 26.12 (5.19)                | r:-0.121                    | r:-0.094             | 23.72 (5.87)                         | 26.75 (7.33)                          |
| **P value**                          | .631§                       | .19                         | .12||                      | .18§                 |                                       |                                        |
| Gender                               |                            |                             |                            |                      |                                       |                                        |
| Female                               | 39 (41.5%)                  | 3 (11.5%)                   | 4.3                         | 5.5 (3)              | 4 (100.0%)                           | 42 (36.2%)                            |
| Male                                 | 55 (58.5%)                  | 23 (88.5%)                  | 5.0                         | 7 (4)                | 4 (100.0%)                           | 74 (63.8%)                            |
| **P value**                          | .005§                       | .11                         | .039†                       | .99§                 |                                       |                                        |
| Diagnosis                            |                            |                             |                            |                      |                                       |                                        |
| Mass, Malignant                      | 75 (79.8%)                  | 24 (92.3%)                  | 5 (3)                       | 6 (3)                | 4 (100.0%)                           | 95 (81.9%)                            |
| Bronchiectasis                       | 4 (4.3%)                    | 1 (3.8%)                    | 7 (4)                       | 8 (1)                | 5 (4.3%)                             |                                        |
| Hydatid cyst                         | 8 (8.5%)                    | 1 (3.8%)                    | 5 (2)                       | 5 (2)                | 9 (7.8%)                             |                                        |
| Pleural Thickening                   | 2 (2.1%)                    | –                           | 3 (2)                       | 3 (2)                | 2 (1.7%)                             |                                        |
| Interstitial Lung                    | 2 (2.1%)                    | –                           | 4.5 (3)                     | 4.5 (3)              | 2 (1.7%)                             |                                        |
| Disease                              | Other                       | 3 (3.2%)                    | 6 (1)                       | 8 (2)                | 3 (2.6%)                             |                                        |
| **P value**                          | .066§                       | .582†                       | .075§                       | .99§                 |                                       |                                        |

Continuous variables are expressed as either the mean ± standard deviation or median (interquartile range) and categorical variables are expressed as either frequency or percentage. It is evaluated the degrees of the relationship between variables with Spearman correlation analysis. r: correlation analysis. P-values marked with bold indicate statistically significant P-values.

*Student t-test.
†Mann-Whitney-U test.
‡Kruskal Wallis.
§Chi-square test.
∥Spearman correlation analysis.

BMI = body mass index, OLV = one lung ventilation, PPCs = postoperative pulmonary complications, VATS = video-assisted thoracic surgery.

Table 4
PPCs, chest tube removal time, discharge time, and 3-month mortality characteristics by patients’ surgical characteristics

|                                      | PPCs positive n:94 (78.3%) | PPCs negative n:26 (21.7%) | Chest tube removal time (Day) | Discharge time (Day) | 3-Month mortality Positive n:4 (3.3%) | 3-Month mortality Negative n:116 (96.7%) |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------|---------------------------------------|----------------------------------------|
| Operation side                       |                            |                             |                            |                      |                                       |                                        |
| Left                                 | 43 (45.7%)                  | 13 (50.0%)                  | 5 (3)                       | 7 (3)                | 4 (100.0%)                           | 52 (44.8%)                            |
| Right                                | 51 (54.3%)                  | 13 (50.0%)                  | 4.5 (4)                     | 5.5 (3)              | –                                     | 64 (55.2%)                            |
| **P value**                          | .70§                       | .18                         | .098†                       | .045§                |                                       |                                        |
| Operation                            | Lobectomy wedge, segment   | 69 (73.4%)                  | 25 (96.2%)                  | 5 (3)                | 6 (4)                                 | 4 (100.0%)                            | 90 (77.6%)                             |
| **P value**                          | .013§                       | <.001†                      | .20†                       | .576§                |                                       |                                        |                                        |
| Pneumonectomy                        | 8 (8.5%)                    | 1 (6.5)                     | 1 (6.5)                     | 7 (6.5)              | –                                     | 8 (6.9%)                              |
| **P value**                          | .199§                       | <.001†                      | .184†                       | .99§                 |                                       |                                        |                                        |
| Decortication                        | 4 (4.3%)                    | –                           | 6.5 (2)                     | 6.5 (2)              | –                                     | 4 (3.4%)                              |
| **P value**                          | .576§                       | .385†                       | .99†                       | .99§                 |                                       |                                        |                                        |
| Other                                 | 16 (17.0%)                  | 1 (3.8%)                    | 4 (3)                       | 4 (3)                | 1 (25.0%)                            | 16 (13.8%)                            |
| **P value**                          | .12§                       | .20†                       | .009†                       | .462§                |                                       |                                        |                                        |
| Operation type                       | VATS                        | 67 (71.3%)                  | 17 (65.4%)                  | 5 (3)                | 6 (3)                                 | 4 (100.0%)                            | 80 (69.0%)                             |
| **P value**                          | .562§                       | .657†                      | .001†                       | .315§                |                                       |                                        |                                        |
| Thoracotomy                          | 42 (44.7%)                  | 12 (46.2%)                  | 6 (3)                       | 7 (2)                | 1 (25.0%)                            | 53 (45.7%)                            |
| **P value**                          | .89§                       | .037†                      | .001†                       | .626§                |                                       |                                        |                                        |
| VATS + thoracotomy                   | 6 (6.4%)                    | –                           | 6 (2)                       | 6.5 (1)              | –                                     | 6 (5.2%)                              |
| **P value**                          | .338§                       | .637†                      | .683†                       | .99§                 |                                       |                                        |                                        |
| Operation duration                   | 186.5 (95)                  | 236.5 (51)                  | r:0.499                     | r:0.473              | 241.5 (98.5)                         | 204 (95)                              |
| **P value**                          | .807†                       | <.001||                     | <.001||                     | .421†                 |                                       |                                        |                                        |
| OLV duration                         | 150 (85)                    | 200 (88)                    | r:0.458                     | r:0.408              | 222.5 (105)                          | 155 (89)                              |
| **P value**                          | .009†                       | <.001||                     | <.001||                     | .24†                  |                                       |                                        |                                        |

Continuous variables are expressed as either the mean ± standard deviation or median (interquartile range) and categorical variables are expressed as either frequency or percentage. It is evaluated the degrees of the relationship between variables with Spearman correlation analysis. r: correlation analysis. P-values marked with bold indicate statistically significant P-values.

*Student t-test.
†Mann-Whitney-U test.
‡Kruskal Wallis.
§Chi-square test.
∥Spearman correlation analysis.

BMI = body mass index, OLV = one lung ventilation, PPCs = postoperative pulmonary complications, VATS = video-assisted thoracic surgery.
time to discharge and chest tube removal. The increase in duration of OLV and surgery was also related to a higher rate of PPCs, and they prolonged the time of discharge and chest tube removal time. While the rate of PPCs was found to be higher in patients who underwent lobectomy, wedge resection, and segmentectomy; the time of chest tube removal was also longer in these patients. We observed that the PPCs could be predicted with the ARISCAT risk index and ASA physical status classification. In patients with PPCs; the duration of surgery and the duration of OLV time were found to be longer. Low preoperative albumin levels were associated with 3-month mortality. In addition to ARISCAT scoring, using ASA physical status and albumin data in combination together can be efficient in predicting PPCs that may develop after thoracic surgery.

Due to the nature of thoracic surgery, intervention in the thoracic cavity is an important factor in the increase of PPCs. In addition, the current clinical status of these patients can frequently deteriorate, which causes many laboratory parameters to be unstable. Thoracic surgery itself is included in the ARISCAT parameters, causing the score to be higher. Therefore, the preoperative ARISCAT scores in thoracic surgery are usually intermediate and high grade. Based on this, we particularly evaluated the effectiveness of the ARISCAT scoring system together with ASA physical status, and albumin level which is an effective parameter in major surgeries such as thoracic surgery.

### Table 5

| Preoperative scores | PPCs negative n:94 (78.3%) | PPCs positive n:26 (21.7%) | Chest tube removal time (day) | Discharge time (day) | 3-Month mortality positive n:4 (3.3%) | 3-Month mortality negative n:116 (96.7%) |
|---------------------|-----------------------------|-----------------------------|-----------------------------|---------------------|--------------------------------------|---------------------------------------|
| ARISCAT score       |                             |                             |                             |                     |                                      |                                       |
| Low                 | 4 (4.3%)                    | –                           | 3 (1.5)                     | 3 (2)               | –                                    | 4 (3.4%)                              |
| Intermediate        | 41 (43.6%)                  | 4 (15.4%)                   | 4 (2)                       | 5 (3)               | 1 (25.0%)                            | 44 (37.9%)                            |
| High                | 49 (52.1%)                  | 22 (84.6%)                  | 6 (3)                       | 7 (2)               | 3 (75.0%)                            | 68 (58.6%)                            |
| P value             | .009†                       | .004†                       | .000‡                       | .000‡               | .000‡                                | .000‡                                 |
| ARISCAT Score       | 47 (7)                      | 50 (0)                      | r:0.320                     | r:0.377             | 54 (11.5)                            | .99§                                  |
| P value             | .002‡                       | .001||                      | .001||                      | .001||                            | .13†                                  |
| ASA                 |                             |                             |                             |                     |                                      |                                       |
| ASA II              | 47 (50.0%)                  | 4 (15.4%)                   | 4 (4)                       | 6 (3)               | 1 (25.0%)                            | 50 (43.1%)                            |
| P value             | .002§                       | .010†                       | .636 §                      |                     |                                      |                                       |
| NRS                 |                             |                             |                             |                     |                                      |                                       |
| 0                   | 84 (89.4%)                  | 23 (88.5%)                  | 5 (3)                       | 6 (4)               | 4 (100.0%)                           | 103 (88.8%)                           |
| 1                   | 7 (7.4%)                    | 2 (7.7%)                    | 4 (2)                       | 5 (3)               | –                                    | 9 (7.8%)                              |
| 2                   | 3 (3.2%)                    | 1 (3.8%)                    | 4 (4)                       | 6 (2.5)             | –                                    | 4 (3.5%)                              |
| P value             | .999§                       | .29†                        | .397‡                       | .99§                |                                      |                                       |
| Albumin (g/L)       | 40.58 ± 4.47                | 40.00 ± 4.13                | r:0.015                     | r:0.081             | 34.68 ± 3.68                         | 40.65 ± 4.28                          |
| P value             | .558*                       | .87||                       | .382||                      | .007*                |                                      |                                       |
| NLR                 | 2.38 (1.3)                  | 2.24 (1.56)                 | r:0.018                     | r:0.032             | 2.94 (2.96)                          | 2.34 (1.31)                           |
| P value             | 0.500†                      | 0.847||                     | 0.725||                     | 0.456†                |                                      |                                       |
| Hemoglobin (g/dL)   | 14.0 ± 1.71                 | 14.34 ± 1.72                | r:0.035                     | r:0.062             | 14.30 ± 1.35                         | 14.11 ± 1.72                          |
| P value             | .45*                        | .702||                       | .50||                       | .83*                  |                                      |                                       |

### Table 6

| Preoperative combinations | PPCs negative n:94 (78.3%) | PPCs positive n:26 (21.7%) | Chest tube removal time (day) | Discharge Time (day) | 3-Month mortality positive n:4 (3.3%) | 3-Month mortality negative n:116 (96.7%) |
|---------------------------|-----------------------------|-----------------------------|-----------------------------|---------------------|--------------------------------------|---------------------------------------|
| Combination-I (n:7)       |                             |                             |                             |                     |                                      |                                       |
| ARISCAT Grade High + Albumin<35g/L + ASA 3 | 3 (11.1%)                  | 4 (80.0%)                   | 7 (8)                       | 8 (7)               | 1 (100.0%)                           | 6 (19.4%)                             |
| Combination-II (n:9)      |                             |                             |                             |                     |                                      |                                       |
| ARISCAT Grade Low and Intermediate + Albumin 35g/L and above + ASA 2 | 8 (88.9%)                  | 1 (20.0%)                   | 4 (2)                       | 4 (2)               | –                                    | 25 (80.6%)                            |
| P value                   | .004†                       | .002*                       | .003*                       |                     | .219†                                |                                       |

Continuous variables are expressed as either the mean ± standard deviation or median (interquartile range) and categorical variables are expressed as either frequency or percentage. It is evaluated the degrees of the relation between variables with Spearman correlation analysis. r: correlation analysis. P-values marked with bold indicate statistically significant P-values.

*Student t-test.
†Mann–Whitney U test.
§Kruskal Wallis.
∥Chi-square test.
‡Kruskal Wallis.
¶Chi-square test.
°Mann-Whitney-U test.
*Student t-test.
†Chi-square test.
ARISCAT = Assess Respiratory Risk in Surgical Patients in Catalonia, ASA = American Society of Anesthesiologists, NLR = Neutrophil -to-Lymphocyte Ratio, NRS = Nutritional risk screening, PPCs = Postoperative Pulmonary Complications.
Studies have shown that advancing age is an important factor in the development of PPCs. Additionally, it has been stated that the male gender is a risk factor for the development of PPCs. Another effective factor in the development of PPCs is the duration of surgery. The duration of surgery, which is also a parameter in ARISCAT scoring, especially over 2 hours has been stated as a significant factor in the development of PPCs. In this study, the results are compatible with the literature; male gender, advancing age, and duration of surgery are among the predictable factors in the development of PPCs.

In a study by Kupeli et al. in which they investigated the relationship between PPCs and ASA physical status, they observed that ASA physical status was a weak modality in predicting the PPCs. At the same time, in their study, the relationship between ARISCAT and PPCs was also evaluated. They concluded that PPCs could be predicted more reliably with the ARISCAT risk index. ASA physical status assessment is routinely used as the parameter in ARISCAT scoring, especially over 2 hours has been stated as a significant factor in the development of PPCs. In conclusion, it was seen that the ARISCAT scoring system was more effective in predicting PPCs after thoracic surgery when used together with ASA physical status and preoperative albumin level. Age, male gender, duration of surgery, and duration of OLV were also associated with PPCs. We think that multicenter studies to be conducted in more specific patient groups can more clearly determine the parameters that are successful in estimating PPCs.

Author contributions:
Conceptualization: HS, GU, AA
Data curation: GU, MZ, RB, OK
Formal analysis: GU, MZ, RB
Investigation: AA, MZ, FI
Methodology: GU, AA, MZ, HS
Project administration: GU, HS, AA, RB
Resources: GU, RB, OK, FI
Supervision: HS, AA, GU, RB
Visualization: AA, GU, MZ
Writing—original draft: All authors
Writing—review & editing: All authors

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgments
We thank Esra Arslanoğlu for their valuable contributions to medical statistics.

References

[1] Miskovic A, Lumb AB. Postoperative pulmonary complications. Br J Anaesth. 2017;118:317–34.
[2] Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of physicians. Ann Intern Med. 2006;144:581–95.
[3] Lakshminarasmiahchar A, Smetana GW. Preoperative evaluation: estimation of pulmonary risk. Anesthesiol Clin. 2016;34:71–88.
[4] Agostini P, Cieslik H, Rathinam S, et al. Postoperative pulmonary complications following thoracic surgery: are there any modifiable risk factors? Thorax. 2010;65:815–8.
[5] Garcia-Miguel FJ, Serrano-Aguilar PG, Lopez-Bastida J. Preoperative assessment. Lancet (London, England). 2003;362:1749–57.
[6] Saracoglu A, Yavru A, Kucukgoncu S, et al. Predictive factors involved in development of postoperative pulmonary complications. Turk J Anaesthesiol Reanim. 2014;42:313–9.
[7] Hightower CE, Riedel BJ, Feig BW, et al. A pilot study evaluating predictors of postoperative outcomes after major abdominal surgery: physiological capacity compared with the ASA physical status classification system. Br J Anaesth. 2010;104:465–71.
[8] Doyle DJ, Goyal A, Bansal P, Garmon EH. American Society of Anesthesiologists Classification. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC, 2021.
[9] Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2016;125:538–50.
[10] Mazo V, Sabaté S, Canet J, et al. Prospective external validation of a predictive score for postoperative pulmonary complications. Anesthesiology. 2014;121:219–31.
[11] Tang Y, Li G, Wu S, et al. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: prognostic significance and association with inflammatory biomarkers. Oncol Lett. 2018;15:4988–96.
[12] Gusdon AM, Gialdini G, Kone G, et al. Neutrophil-lymphocyte ratio and perihematoma edema growth in intracerebral hemorrhage. Stroke. 2017;48:2589–92.

[13] Ögren E, Güzel M, Akpinar CK, et al. The relationship between neutrophil/lymphocyte, monocyte/lymphocyte, platelet/lymphocyte ratios and clinical outcomes after ninety days in patients who were diagnosed as having acute ischemic stroke in the emergency room and underwent a mechanical thro. Bratisl Lek Listy. 2020;121:634–9.

[14] Varman A, Alkan S. Evaluation of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, mean platelet volume, and neutrophil/monocyte ratio in patients with benign breast lesions. Bratisl Lek Listy. 2021;122:489–92.

[15] Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer. 2010;10:2–3.

[16] Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018;267:527–31.

[17] Chen WS, Huang YS, Xu LB, et al. Effects of sarcopenia, hypoalbuminemia, and laparoscopic surgery on postoperative complications in elderly patients with colorectal cancer: A prospective study. Neoplasma. 2020;67:922–32.

[18] Gurr HS, Bhurt DL, Lincoff AM, et al. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPilogue, and EPISENT trials. Heart (British Cardiac Society). 2003;89:1200–4.

[19] Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol. 2005;15:256–71.

[20] Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45:1638–43.

[21] Jammer I, Wickboldt N, Sander M, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative medicine. Eur J Anaesthesiol. 2015;32:88–105.

[22] Lederman D, Easwar J, Feldman J, et al. Anesthetic considerations for McKeown esophagectomy. Tumori. 2020;106:47–54.

[23] Tatak KM, Fitke MM, Shingada KV. Study of risk, incidence and mortality associated with postoperative pulmonary complications using assess respiratory risk in surgical patients in catalonia score. Int Surg J. 2019;2019:3215–22.

[24] Kupeli E, Er Dedekarginoglu B, Ulubay G, et al. American Society of anesthesiologists classification versus ARISCAT risk index: predicting pulmonary complications following renal transplant. Exp Clin Transplant. 2017;15(Suppl 1):208–13.

[25] Li C, Yang WH, Zhou J, et al. Risk factors for predicting postoperative complications after open infrarenal abdominal aortic aneurysm repair: results from a single vascular center in China. J Clin Anesth. 2013;25:371–8.

[26] Robinson TN, Wu DS, Pointer L, et al. Simple frailty score predicts postoperative complications across surgical specialties. Am J Surg. 2013;206:544–50.

[27] Ramachandran SK, Nafiu OO, Ghaferi A, et al. Independent predictors and outcomes of unanticipated early postoperative tracheal intubation after nonemergent, noncardiac surgery. Anesthesiology. 2011;115:44–33.

[28] Aronson WL, McAliffe MS, Miller K. Variability in the American Society of anesthesiologists physical status classification scale. AANA J. 2003;71:265–74.

[29] Aldedeyan S, Nooh A, Aoude A, et al. Hypoalbuminemia—a marker of malnutrition and predictor of postoperative complications and mortality after hip fractures. Injury. 2017;48:436–40.

[30] Hardt J, Pile L, Magdeburg J, et al. Preoperative hypoalbuminemia is an independent risk factor for increased high-grade morbidity after elective rectal cancer rection. Int J Colorectal Dis. 2017;32:1439–46.

[31] Uppal S, Al-Niaimi A, Rice LW, et al. Preoperative hypoalbuminemia is an independent predictor of poor perioperative outcomes in women undergoing open surgery for gynecologic malignancies. Gynecol Oncol. 2013;131:416–22.

[32] Li P, Li J, Lai Y, et al. Perioperative changes of serum albumin are a predictor of postoperative pulmonary complications in lung cancer patients: a retrospective cohort study. J Thorac Dis. 2018;10:5755–63.

[33] Karzai W, Schwarzkopf K. Hypoxemia during one-lung ventilation: prediction, prevention, and treatment. Anesthesiology. 2009;110:1402–11.

[34] Loeb J, Slinger P. Lung injury after one-lung ventilation: a review of the pathophysiologic mechanisms affecting the ventilated and the collapsed lung. Anesth Analg. 2015;121:302–18.

[35] Lai G, Guo N, Jiang Y, et al. Duration of one-lung ventilation as a risk factor for postoperative pulmonary complications after McKeown esophagectomy. Tumori. 2020;106:47–54.

[36] Fiorelli S, Defraia V, Cipolla F, et al. Short-term one-lung ventilation does not influence local inflammatory cytokine response after lung resection. J Thorac Dis. 2018;10:1864–74.